Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Prozac clears FDA

Executive Summary

FDA clears Lilly's Prozac (fluoxetine) for treatment of major depressive disorder and obsessive compulsive disorder in children seven to 17 Jan. 3. The company received additional market exclusivity from February 2001 until August 2001 for conducting the pediatric trials. As a Phase IV postmarketing commitment, Lilly will "evaluate any potential impact of fluoxetine on long-term growth in children," an FDA 1talk paper says...

You may also be interested in...

Pediatric Prozac Phase IV Commitments Will Test Exclusivity Incentive

Lilly's Phase IV commitments for additional research on pediatric use of Prozac will serve as a high-profile test of FDA's pediatric exclusivity incentive

Daiichi's Novel EZH Candidate Moves Ahead With New Consortium Trial

Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

Executive order calls for short-term and long-term study, broad consultation, coordination with allies.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts